[Clinical analysis of 126 cases with NHL in extra-node of head and neck patients in stage I and II].
From 1987.1.1. to 1990. 12. 31. 126 cases of extranode untreated non-Hodgkin's lymphoma (NHL) in I-II stage were analysed. All of the 126 cases had proved by pathology. The sites of primary disease were oral-pharynx in 64.3%, nasal cavity in 31% and others in 4.7%. The age of patients was between 5-69 (30-60 in 62.7%). According to the international working dassification, there was 1 case of low grade, 48 (38%) of intermediate and 77(61%) of high grade. According to Ann Arbor clinical staging, there were 33 cases of stage I and 93 cases of stage II. According to the pathological grades and clinical stages, the treatment was divided into 4 groups. (1) CT-RT 63 cases, (2) RT-CT 26 cases, (3) RT 32 cases and (4) CT 5 cases. After treatment, CR were obtained in 101 cases, PR 18 cases and P 3 cases, CR+PR were 97.5%. The 1,2,3,4,5 years survival rates of the 126 cases were 83.3% (105/126), 70.6% (89/126), 68.2% (60/88), 62.2% (46/74), 58.3% (21/36), respectively.


CONCLUSIONS
(1) The pathological grades were not closely related to the survival rate of patients. (2) The comparison of clinical stages I:II showed a P value < 0.05. (3) The comparison of survival rates of CR:PR:P showed a P value < 0.05 and < 0.001, respectively. (4) There was no statistically significant difference in the four treatment protocols. But the multitherapy group was better. (5) Before the RT, four cycles of CT showed a better result than that of 1-3 cycles.
Wang
Q L
QL
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing.
Zhou
L Q
LQ
Zhang
P
P
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006258:Head and Neck Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011241:Prednisone / Q000008:administration & dosage; D015996:Survival Rate; D014750:Vincristine / Q000008:administration & dosage
D001761:Bleomycin; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone